<DOC>
	<DOCNO>NCT01997983</DOCNO>
	<brief_summary>The investigator believe study importance several aspect : 1 . It evaluate new mode bladder instillation may bypass drawback current instillation mode . 2 . It demonstrate safety intravesical instillation BTX mix TC-3 gel IC patient 3 . If prove effective partially effective , mode treatment serve basis large feasibility study explore safety efficacy aspect .</brief_summary>
	<brief_title>Efficacy Safety Intravesical Instillations Botulinum Toxin TC-3 Gel IC Patients</brief_title>
	<detailed_description>American Urology Association ( AUA ) consider intradetrusor injection BTX fifth-line treatment interstitial cystitis due seriousness adverse event , include dysuria , large post-void residual , need intermittent self-catheterization . An appeal alternative BTX injection intravesical instillation BTX since recent study suggest intravesically apply BTX act afferent neuropathway involve sensory mechanism urothelium rather smooth muscle . TheraCoat core technology base reverse thermal biodegradable gel ( TC-3 ) ( low viscosity 5Â°C gel appearance body temperature ) drug retention urinary bladder . Intravesical BTX instillation use TheraCoat gel expect increase treatment efficiency due prolongation treatment duration consequently improve bladder exposure BTX . Prior instillation , TC-3 hydrogel , liquid state , mixed BTX.TC-3 mixed BTX instill bladder catheter . Following gel insertion bladder , gel solidifies form drug reservoir inside bladder . Upon contact urine gel dissolve clear bladder Post instillation , patient follow 2 , 6 , 12 week thereafter .</detailed_description>
	<mesh_term>Cystitis</mesh_term>
	<mesh_term>Cystitis , Interstitial</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<criteria>1 . Subject diagnosed Interstitial Cystitis/PBS . 2 . Subject sign Informed Consent Form willing able abide protocol . 3 . Subject IC Symptom index ( IC Symptom Problem Questionnaire ) score 1220 point . 4 . Subject IC Problem index ( IC Symptom Problem Questionnaire ) score 1216 point . 5 . Subject willing able complete micturition diary questionnaire correctly . 6 . Subject agree available followup evaluation require protocol . 7 . Subject mentally competent ability understand comply requirement study . 8 . No active urinary tract infection confirm urine culture . 9 . If subject female childbearing potential negative pregnancy test screening . 1 . Patient pregnant , lactating , plan become pregnant within study period . 2 . Patient use Clean Intermittent Catheterization ( CIC ) . 3 . Patient known neurological cause IC/PBS symptom . 4 . Patient Patient implant permanent neurostimulation device 5 . Patient pelvic organ prolapse stage III IV , ( i.e . distal part prolapse protrude 1 cm beyond hymen strain ) 6 . Patient low tract genitourinary malignancy 7 . Patient prior antiincontinence surgery intervention include midurethral sling , burch bladder suspension , sacral neuromodulation , tibial nerve stimulation . 8 . Patient receive intradetrusor Botox ( Botolinum Toxin A ) injection within 12 month prior study initiation . 9 . Patient previous pelvic radiation therapy 10 . Patient morbidly obese ( BMI &gt; 40 Kg/m2 ) . 11 . Patient current cultureproven urinary tract infection , include cystitis urethritis . 12 . Patient treat 2 UTIs within last 6 month . 13 . Patient life expectancy le 12 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>interstitial cystitis</keyword>
	<keyword>PBS/IC</keyword>
	<keyword>IC</keyword>
	<keyword>Botox</keyword>
	<keyword>Botulinum toxin</keyword>
	<keyword>TC-3 Gel</keyword>
	<keyword>TCGel</keyword>
	<keyword>TheraCoat</keyword>
</DOC>